aliskiren vs trandolapril
According to this portal's Publishing Organization, this page was last reviewed in August 2026 against our methodology. Figures and extracts on this site, including tables above 1,000 rows when the corpus is that large, are the publisher's responsibility.
Side-by-side comparison of aliskiren and trandolapril. Data from FDA drug databases (Orange Book, NDC Directory, recalls, shortages) covering 20,000+ approved drugs, plus CMS pricing; see our methodology.
major Known Drug Interaction
Drug Interactions Dual Blockade of the Renin-Angiotensin System (RAS) Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. Do not co-administer aliskiren with trandolapril in patients with diabetes. Avoid use of aliskiren with trandolapril in patients with renal impairment (GFR <60 mL/min).
Tekturna
Mavik
Tekturna is a medicine used to treat high blood pressure. It helps lower blood pressure, which can reduce the risk of strokes and heart attacks.
Trandolapril (Mavik) is a medicine that lowers blood pressure. It can also help people who have had a heart attack and have a weak heart.
Tekturna is used to treat high blood pressure in adults and children who weigh at least 110 pounds and are 6 years or older. Lowering your blood pressure helps prevent strokes and heart attacks. It is important to manage high blood pressure with a healthy lifestyle too.
Trandolapril is used to treat high blood pressure. It can be used alone or with other blood pressure medicines. It is also used in people who have had a heart attack and have a weak heart (left ventricular dysfunction) or heart failure.
Tekturna works by blocking a substance in your body called renin. Renin helps to control your blood pressure. By blocking renin, Tekturna helps to lower your blood pressure.
Trandolapril belongs to a class of drugs called ACE inhibitors. It works by blocking a substance in your body that tightens blood vessels. This helps your blood vessels relax and lowers your blood pressure.
- • Diarrhea
- • Cough
- • Dizziness
- Asthenia 367
- Fall 356
- Nausea 336
- Dyspnoea 315
- Headache 301
- Dyspnoea 137
- Fatigue 119
- Dizziness 108
- Diarrhoea 99
- Cough 97
Tekturna can harm your unborn baby, even causing death. If you become pregnant, stop taking Tekturna right away and tell your doctor.
If you become pregnant, stop taking trandolapril right away. This medicine can harm or cause death to your unborn baby.
Tekturna can cause serious harm or death to an unborn baby. If you are pregnant or plan to become pregnant, talk to your doctor about other blood pressure medicines. Breastfeeding is not recommended while taking Tekturna.
Do not take trandolapril if you are pregnant. It can cause serious harm to your unborn baby. Talk to your doctor about other blood pressure medicines if you are breastfeeding.
Also Compare, Nearby Drugs
Compare trandolapril with
How to Read This aliskiren vs trandolapril Comparison
aliskiren is classified in the Direct Renin Inhibitor drug class, while trandolapril sits within the ACE Inhibitor class. Drugs from different classes work through distinct mechanisms, so a head-to-head comparison illustrates trade-offs rather than equivalence. Both drugs are prescription-only, so a licensed provider must authorize use.
Adverse event totals above are pulled from the FDA's Adverse Event Reporting System (FAERS). For these top-ranked reactions alone, aliskiren has 1,675 submissions while trandolapril has 560. Those figures reflect cumulative reporting volume, not per-patient risk, so older, widely dispensed drugs typically look worse on count alone. These two drugs have a known major interaction flagged in FDA labeling, attributed to both drugs target the same system for controlling blood pressure, which can overwork the kidneys. this increases the risk of very low blood pressure and high potassium levels.. Serious warnings, pregnancy guidance, and contraindications can differ even when indications overlap.
A table cannot represent individual circumstances. Data here is sourced from FDA Structured Product Labels (SPL) and FAERS, both of which update as manufacturers and clinicians submit new information. This registry does not provide medical, treatment, substitution, or medication-change directions for aliskiren or trandolapril.
Registry boundary: This comparison displays source-record fields and does not provide individualized medical direction.